Evidera is pleased to congratulate our own Eric Faulkner, MPH, Vice President, Precision and Transformative Technology Solutions, on his recent collaboration with The Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) on a study of payer and provider medical director perspectives on value demonstration and reimbursement for regenerative and advanced therapies.
The study publication, “Ensuring Patient Access to Regenerative and Advanced Therapies in Managed Care: How Do We Get There?,” was announced in a joint ARM and NAMCP press release on January 30. The assessment identifies various challenges and posits possible solutions to ensure the appropriate integration of these high-value therapies into the current U.S. healthcare system. The study also takes a look at various alternative payment and financing models to enable sustainable patient access to these products.
As lead author for the publication, Eric Faulkner commented, “This is a critical time for dialogue between regenerative and advanced therapy manufacturers, managed care, and other stakeholders. Our health system is continuously seeking innovations that have the potential to transform patient outcomes and truly ‘move the needle.’ Regenerative and advanced therapies have such potential, but they will enter global health systems that are ill-prepared to receive truly transformative therapies. This paper is part of the vanguard of early global dialogue to help bridge this gap and help prepare us for novel technologies that may alter our expectations for therapy development and patient care.”
“This study highlights Evidera’s commitment to help optimize access to health technologies with significant potential to improve patient health – such as precision medicines; cell, gene, and regenerative therapies; specialty treatments; novel biologics; and, e-connective technologies,” stated Jon Williams, President of Evidera. “These therapies often have more complex value demonstration, market access, and commercial issues as compared to conventional pharmaceuticals. Recognizing these differences, Evidera’s team of scientists and consulting executives are focused on developing actionable novel and custom-tailored approaches to support these technologies.”
Contact us here to learn more about the study or to find out more about how we can help you with your patient access challenges.